Amanote Research

Amanote Research

    RegisterSign In

Class Effects of SGLT2 Inhibitors on Cardiorenal Outcomes

Cardiovascular Diabetology - United Kingdom
doi 10.1186/s12933-019-0903-4
Full Text
Open PDF
Abstract

Available in full text

Categories
Internal MedicineCardiologyEndocrinologyCardiovascular MedicineMetabolismDiabetes
Date

August 5, 2019

Authors
Aaron Y. KlugerKristen M. TecsonAndy Y. LeeEdgar V. LermaJanani RangaswamiNorman E. LeporMichael E. CobblePeter A. McCullough
Publisher

Springer Science and Business Media LLC


Related search

SGLT2 Inhibitors

2020English

SGLT2 Inhibitors: Mind the Gap

Chest
CardiologyCritical CareCardiovascular MedicineIntensive Care MedicinePulmonaryRespiratory Medicine
2016English

SGLT2 Inhibitors for Primary Prevention of Cardiovascular Events

Journal of Diabetes
EndocrinologyMetabolismDiabetes
2019English

Is Cancer Incidence Modified by SGLT2 Inhibitors?

Diabetes Mellitus
Internal MedicineEndocrinologyMetabolismDiabetes
2019English

SGLT2 Inhibitors: Alternatives or Complementary Therapeutic Options

2020English

Effects of SGLT2 Inhibitors in the Treatment of a Population With Type 2 Diabetes Mellitus

Endocrine Abstracts
2016English

Discovery of Natural SGLT2-Inhibitors for Type 2 Diabetes – Possible Way to Reduce Side Effects

Journal of Natural Remedies
Pharmacology
2016English

Sarcopenia, Frailty Circle, and Treatment With SGLT2 Inhibitors

Journal of Diabetes Investigation
Internal MedicineEndocrinologyMetabolismMedicineDiabetes
2018English

Diabetes Research Open Access: Sodium Glucose Cotransporter2 (SGLT2) Inhibitors

2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy